Literature DB >> 28521675

Chemotherapy with si-RNA and Anti-Cancer Drugs.

Kamaljeet Kaur1, Goutam Rath1, Saket Chandra1, Ranjit Singh1, Amit Kumar Goyal1.   

Abstract

BACKGROUND: To treat cancer, chemotherapy is a key therapeutic approach which is associated with several limitations. This chemotherapeutical agent exhibits multi drug resistance coupled with undesirable side effects. This multidrug resistance is exhibited by tumor cell due to actuation of drug out flow mechanism, programmed cell death and protection mechanisms etc. One of the therapeutic approaches to cure cancer is RNA interference (RNAi). Small interfering RNA (si-RNA) is considered as a major therapeutic tool used to control expression of a particular gene. It is a well known fact that intake of more drugs can lead to cancer chemo resistance, thus siRNA based therapeutic approach is under scrutiny to cure cancer.
METHODS: This review article gives an overview of various combination approaches for si-RNA with chemotherapeutics. Further, article highlights the potential of nanotechnology to improve bioavailability of drug and bio-therapeutics at the site of action.
RESULTS: Combination chemotherapy is employed in clinics as a main cancer treatment tool to suppress multidrug resistance in cancer. On the other hand, suitable protective carrier is needed due to the stability issues and small size of si-RNA. To overcome these drawbacks associated with siRNA currently, nanotechnology based approaches have been widely used.
CONCLUSION: Delivery of anti-cancer drugs with si-RNA will be one of important intermingled approach to reduce duration of chemotherapy and improve therapeutic outcomes in cancer patient. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Nanotechnology; RNAi; cancer; clinical trial; combination therapy; si-RNA

Mesh:

Substances:

Year:  2018        PMID: 28521675     DOI: 10.2174/1567201814666170518141440

Source DB:  PubMed          Journal:  Curr Drug Deliv        ISSN: 1567-2018            Impact factor:   2.565


  5 in total

1.  Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia.

Authors:  Yiqian Wang; Ying Xie; Jacob Williams; Yu Hang; Lisa Richter; Michelle Becker; Catalina Amador; David Oupický; R Katherine Hyde
Journal:  Cancer Gene Ther       Date:  2019-04-26       Impact factor: 5.987

2.  Tumour-Targeted and Redox-Responsive Mesoporous Silica Nanoparticles for Controlled Release of Doxorubicin and an siRNA Against Metastatic Breast Cancer.

Authors:  Jialang Zhuang; Siqi Chen; Ye Hu; Fan Yang; Qin Huo; Ni Xie
Journal:  Int J Nanomedicine       Date:  2021-03-08

3.  Efficient Delivery of Therapeutic siRNA by Fe3O4 Magnetic Nanoparticles into Oral Cancer Cells.

Authors:  Lili Jin; Qiuyu Wang; Jiayu Chen; Zixiang Wang; Hongchuan Xin; Dianbao Zhang
Journal:  Pharmaceutics       Date:  2019-11-17       Impact factor: 6.321

4.  Berberine Reverses Breast Cancer Multidrug Resistance Based on Fluorescence Pharmacokinetics In Vitro and In Vivo.

Authors:  Ke Qian; Chao-Yuan Tang; Li-Ying Chen; Shuang Zheng; Yue Zhao; Li-Sha Ma; Li Xu; Lu-Hui Fan; Jian-Dong Yu; Hong-Sheng Tan; Ya-Lan Sun; Li-Li Shen; Yang Lu; Qi Liu; Yun Liu; Yang Xiong
Journal:  ACS Omega       Date:  2021-04-13

Review 5.  Combination of Anti-Cancer Drugs with Molecular Chaperone Inhibitors.

Authors:  Maxim Shevtsov; Gabriele Multhoff; Elena Mikhaylova; Atsushi Shibata; Irina Guzhova; Boris Margulis
Journal:  Int J Mol Sci       Date:  2019-10-24       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.